CERo Therapeutics, Inc.
Multi-functional engineered T cells for cancer immunotherapy
- Sector
- Biotech
- Headquarters
- SAN FRANCISCO, CA
- Founded
- 2016
- Latest Form D
- $43M, Nov 2019
- Total capital
- $45M
- Grants
- —
- No SBIR or STTR on record
- Sector median 1 award
- Raised
- $45M
- 2 Form D · Nov 2019
- 83 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 2 granted · 38 pending
- 20× sector median 2 patents
Capital Timeline
Federal ↑Equity ↓20162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $43,249,966 | |
| Private capital raised | Form D · SEC | $1,399,999 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3388 | Life Biosciences LLC | — | $54M |
| 3389 | PhaseBio Pharmaceuticals Inc | — | $64M |
| 3390 | OPUS GENETICS INC. | — | $47M |
| 3391 | CERo Therapeutics, Inc. | — | $45M |
| 3392 | Forte Biosciences | — | $44M |
| 3393 | Oncotelic Therapeutics, Inc. | — | $40M |
| 3394 | ADVANTAGENE, INC | — | $36M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Daniel CoreyDirector · Executive Officer · Promoter
- Jordan CoreyExecutive Officer · Promoter
- Lawrence CoreyDirector · Executive Officer · Promoter
- Stan RiddellDirector
- Stuart SloanDirector
- Heather TurnerDirector
Patents
- Chimeric Engulfment Receptor Moleculesapplication
- Chimeric TIM4 Receptors And Uses Thereofapplication
- Chimeric Engulfment Receptor Molecules And Methods Of Usegranted
- Chimeric Engulfment Receptor Moleculesgranted
- Bivalent Chimeric Engulfment Receptors And Uses Thereofapplication
- Expression Vectors For Chimeric Engulfment Receptors, Genetically Modified Host Cells, And Uses Thereofapplication
- Chimeric Engulfment Receptors And Uses Thereof For Neurodegenerative Diseasesapplication
- Chimeric Engulfment Receptor Moleculesapplication
- ANTI-CD72 Chimeric Receptors And Uses Thereofapplication
- Chimeric Tim Receptors And Uses Thereofapplication
- Compositions And Methods For Enhancing CCR7 Expressing T Cells Or CD4/CD8 T Cell Ratio With Chimeric TIM4 Receptors In Combination With Inhibitors Of Poly (adp-ribose) Polymeraseapplication
- ANTI-CD72 Chimeric Receptors And Uses Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.